Braveheart Bio, Inc. (BRVE) stock
BRVENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026
$18.53−0.25 (-1.33%)
Close on Nov 18, 2026Market cap $1.67BP/E –Yield –
Braveheart Bio operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$30.15M | – |
| Q2 FY2026 | Jun 30, 2026 | -$15.88M | – |
| Q3 FY2025 | Sep 30, 2025 | -$59.29M | – |
| Q2 FY2025 | Jun 30, 2025 | -$381.00K | – |
See a number that looks wrong?